CoinWorld News reports that Cathie Wood posted on X platform stating that, according to ARK Invest's research, the most far-reaching application of AI will be in healthcare. Deregulation is accelerating this transformation in the healthcare sector. Significant progress has been made in the science of evaluating drug efficacy, with R&D projects collecting evidence across multiple dimensions such as mechanisms of action, biomarker effects, and intermediate endpoints. This validation evidence, from mechanistic data to real-world evidence, can replace the second pivotal trial. Historically, there has been greater regulatory flexibility in rare diseases and oncology, and it is expected that the change from two to one trial will have the greatest impact in common disease areas such as cardiovascular and respiratory diseases, potentially saving up to $350 million per project and shortening R&D cycles by several years.